Extended-release intramuscular naltrexone (VIVITROL®): A review of its use in the prevention of relapse to opioid dependence in detoxified patients

CNS Drugs

Volumn 27, Issue 10, 2013, Pages 851-861

  Syed, Yahiya Y ^a   Keating, Gillian M ^a  

^a Adis 41 Centorian Drive ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMORPHINE; HYDROMORPHONE; METHADONE; NALTREXONE; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANXIETY; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIURIA; BRONCHITIS; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED RELEASE FORMULATION; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DEPRESSION; DETOXIFICATION; DIZZINESS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENDED RELEASE FORMULATION; HEADACHE; HUMAN; HYPERTENSION; INFLUENZA; INJECTION SITE PAIN; INSOMNIA; MEDICATION COMPLIANCE; NAUSEA; OPIATE ADDICTION; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; THROMBOCYTE COUNT; TOOTH PAIN; TREATMENT DURATION; URINARY TRACT INFECTION; VOMITING;

ADULT; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INJECTIONS, INTRAMUSCULAR; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; RECURRENCE;

EID: 84885451037     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-013-0110-x     Document Type: Review

References (29)

1. Tetrault JM, Fiellin DA. Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs. 2012;72(2):217-28.
2. Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: summary of national findings, NSDUH Series H-44, HHS publication no. (SMA) 12-4713. Rockville: Substance Abuse and Mental Health Services Administration; 2012.
3. Birnbaum HG, White AG, Schiller M, et al. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12(4):657-67.
4. World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. 2009. http://www.who.int/ substance-abuse/publications/opioid-dependence-guidelines.pdf. Accessed 22 May 2013.
5. Substance Abuse and Mental Health Services Administration. SAMHSA Advisory: an introduction to extended-release injectable naltrexone for the treatment of people with opioid dependence. 2012. http://store.samhsa.gov/shin/ content//SMA12-4682/SMA12-4682.pdf. Accessed 7 Mar 2013.
6. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375(9719):1014-28.
7. Fishman MJ, Winstanley EL, Curran E, et al. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility. Addiction. 2010;105(9):1669-76.
8. Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506-13.
9. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(2):210-8.
10. Modesto-Lowe V. Naltrexone depot DrugAbuse sciences. IDrugs. 2002;5(8):835-8.
11. Dunbar JL, Turncliff RZ, Dong Q, et al. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone. Alcohol Clin Exp Res. 2006;30(3):480-90.
12. Bartus RT, Emerich DF, Hotz J, et al. Vivitrex, an injectable, extended-release formulation of naltrexone, provides pharmacokinetic and pharmacodynamic evidence of efficacy for 1 month in rats. Neuropsychopharmacology. 2003;28(11):1973-82.
13. ® (naltrexone for extended-release injectable suspension), intramuscular: prescribing information. 2010. http://www.vivitrol.com/Content/pdf/prescribing-info.pdf. Accessed 20 Feb 2013.
14. Alkermes Inc. Annual report on form 10-K for the fiscal year ended March 31, 2012. 2012. http://www.sec.gov/Archives/edgar/data/1520262/ 000104746912006168/a2209642z10-k.htm. Accessed 21 Feb 2013.
15. Swainston Harrison T, Plosker GL, Keam SJ. Extended-release intramuscular naltrexone. Drugs. 2006;66(13):1741-51.
16. Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs. 1988;35(3):192-213.
17. Bigelow GE, Preston KL, Schmittner J, et al. Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course. Drug Alcohol Depend. 2012;123(1-3):57-65.
18. Turncliff RZ, Dunbar JL, Dong Q, et al. Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment. J Clin Pharmacol. 2005;45(11):1259-67.
19. Dunbar JL, Turncliff RZ, Hayes SC, et al. Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. J Stud Alcohol Drugs. 2007;68(6):862-70.
20. Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction. 2013;. doi: 10.1111/add.12208.
21. Earley PH, Gastfriend D, Memisoglu A, et al. Open-label study of intramuscular extended-release naltrexone (XR-NTX) in healthcare professional with opioid dependence [abstract no. NR7-11]. 165th Annual Meeting of the American Psychiatric Association; 5-9 May 2012; Philadelphia, PA.
22. Lee J, Selling D, McDonald R, et al. Extended-release naltrexone (medical management in primary care and) criminal justice settings [oral presentation]. 74th Annual Meeting - College on Problems of Drug Dependence; Jun 9-14 2012; Palm Springs, CA.
23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
24. Gastfriend DR. Physician substance abuse and recovery: what does it mean for physicians-and everyone else? JAMA. 2005;293(12):1513-5.
25. Mitchell MC, Memisoglu A, Silverman BL. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. J Stud Alcohol Drugs. 2012;73(6):991-7.
26. ® (naltrexone for extended-release injectable suspension). 2013. http://www.vivitrol.com/Content/ pdf/medication-guide.pdf. Accessed 22 May 2013.
27. Baser O, Chalk M, Fiellin DA, et al. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011;17(Suppl 8):S235-48.
28. National Institute on Drug Abuse. Extended-release naltrexone vs. buprenorphine for opioid treatment (X:BOT). 2013. http:// ctndisseminationlibrary.org/protocols/ctn0051.htm. Accessed 8 Mar 2013.
29. Silverman B, Gastfriend DR. Safety and effectiveness of treatment with a once-monthly, injectable formulation of naltrexone (XR-NTX) in a real-world clinical practice setting [abstract no. NR7-10]. 165th Annual Meeting of the American Psychiatric Association; 5-9 May 2012; Philadelphia, PA.